Last reviewed · How we verify
ATV/r
ATV/r is a protease inhibitor boosted with ritonavir that blocks HIV protease, preventing viral replication by inhibiting the cleavage of viral polyproteins.
ATV/r is a protease inhibitor boosted with ritonavir that blocks HIV protease, preventing viral replication by inhibiting the cleavage of viral polyproteins. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in combination antiretroviral therapy.
At a glance
| Generic name | ATV/r |
|---|---|
| Also known as | Atazanavir/Ritonavir, Atazanavir/r |
| Sponsor | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
| Drug class | HIV protease inhibitor (boosted) |
| Target | HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Atazanavir (ATV) is an HIV protease inhibitor that binds to and inhibits the HIV protease enzyme, which is essential for processing viral proteins and producing mature, infectious viral particles. Ritonavir (r) is a potent CYP3A4 inhibitor used as a pharmacokinetic booster to increase atazanavir plasma concentrations and half-life, allowing for lower doses and improved dosing convenience. Together, ATV/r suppresses HIV replication and reduces viral load in infected individuals.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced adults
- HIV-1 infection in combination antiretroviral therapy
Common side effects
- Hyperbilirubinemia
- Nausea
- Diarrhea
- Headache
- Rash
- Vomiting
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
- Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine (PHASE3)
- Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial (PHASE2, PHASE3)
- Dose Escalation Study to Determine the Pharmacokinetics of Atazanavir Administered With RIfampicin to HIV Positive Adults on sEcond-line ART Regimen With Suppressed HIV-1 Viral Load (PHASE2, PHASE3)
- Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression (PHASE3)
- ANRS 12372 MODERATO Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ATV/r CI brief — competitive landscape report
- ATV/r updates RSS · CI watch RSS
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections portfolio CI